TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd ( (DRTS) ) just unveiled an update.
On August 27, 2025, Alpha Tau Medical Ltd. announced its participation in five investor conferences in September 2025, where CFO Raphi Levy will present and meet with investors. The company’s Alpha DaRT technology, which aims to treat solid tumors through localized alpha radiation, is being explored for its potential in cancer treatment. This participation in investor conferences highlights Alpha Tau’s efforts to engage with stakeholders and potentially strengthen its market position in the oncology therapeutics industry.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT technology for treating solid tumors. The Alpha DaRT platform is an innovative approach that uses localized alpha particle radiotherapy to destroy solid tumors while sparing healthy tissue, with potential applications in various cancer treatments.
Average Trading Volume: 48,976
Technical Sentiment Signal: Buy
Current Market Cap: $281.2M
See more data about DRTS stock on TipRanks’ Stock Analysis page.